Transcript level of nucleostemin in newly diagnosed acute myeloid leukemia patients

Leukemia Research

Volumn 37, Issue 12, 2013, Pages 1636-1641

  You, Yong ^a   Li, Xiaoqing ^a   Zheng, Jine ^a   Wu, Yaohui ^a   He, Yanli ^a   Du, Wen ^a   Zou, Ping ^a   Zhang, Min ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Acute myeloid leukemia; Minimal residual disease; Nucleostemin; Risk stratification

Indexed keywords

CD123 ANTIGEN; CD34 ANTIGEN; MESSENGER RNA; NUCLEAR PROTEIN; NUCLEOSTEMIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER PROGNOSIS; CHILD; CONTROLLED STUDY; ETO GENE; EVI1 GENE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; SCHOOL CHILD; WT1 GENE;

EID: 84888134858     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.09.023     Document Type: Article

References (38)

1. Welch J.S., Ley T.J., Link D.C., Miller C.A., Larson D.E., Koboldt D.C., et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
2. Walter R.B., Appelbaum F.R., Estey E.H., Bernstein I.D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012, 119:6198-6208.
3. Bachas C., Schuurhuis G.J., Assaraf Y.G., Kwidama Z.J., Kelder A., Wouters F., et al. The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse. Leukemia 2012, 26:1313-1320.
4. Cunningham I. A basis for updating our approach to resistant acute leukemia. Am J Hematol 2012, 87:251-257.
5. Ofran Y., Rowe J.M. Treatment for relapsed acute myeloid leukemia: what is new?. Curr Opin Hematol 2012, 19:89-94.
6. Yin J.A., O'Brien M.A., Hills R.K., Daly S.B., Wheatley K., Burnett A.K. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012, 120:2826-2835.
7. DiNardo C.D., Luger S.M. Beyond morphology: minimal residual disease detection in acute myeloid leukemia. Curr Opin Hematol 2012, 19:82-88.
8. Buccisano F., Maurillo L., Del Principe M.I., Del Poeta G., Sconocchia G., Lo-Coco F., et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012, 119:332-341.
9. Grimwade D., Vyas P., Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010, 22:656-663.
10. Polak J., Hajkova H., Haskovec C., Cechova H., Marinov I., Mikulenkova D., et al. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia-a useful tool for early detection of minimal residual disease. Neoplasma 2013, 60:74-82.
11. Bacher U., Schnittger S., Haferlach T. Molecular genetics in acute myeloid leukemia. Curr Opin Oncol 2010, 22:646-655.
12. Nimer S.D. Is it important to decipher the heterogeneity of "normal karyotype" AML?. Best Pract Res Clin Haematol 2008, 21:43-52.
13. Cazzaniga G., Dell'Oro M.G., Mecucci C., Giarin E., Masetti R., Rossi V., et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 2005, 106:1419-1422.
14. Tsai R.Y., McKay R.D. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 2002, 16:2991-3003.
15. Lo D., Lu H. Nucleostemin: another nucleolar Twister of the p53-MDM2 loop. Cell Cycle 2010, 9:3227-3232.
16. Nomura J., Maruyama M., Katano M., Kato H., Zhang J., Masui S., et al. Differential requirement for nucleostemin in embryonic stem cell and neural stem cell viability. Stem Cells 2009, 27:1066-1076.
17. Lin T., Meng L., Li Y., Tsai R.Y. Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res 2010, 70:9444-9452.
18. Yin C.C., Medeiros L.J., Bueso-Ramos C.E. Recent advances in the diagnosis and classification of myeloid neoplasms-comments on the 2008 WHO classification. Int J Lab Hematol 2010, 32:461-476.
19. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
20. Willasch A.M., Gruhn B., Coliva T., Kalinova M., Schneider G., Kreyenberg H., et al. European Study Group on WT1 Expression in Childhood AML. Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study. Leukemia 2009, 23:1472-1479.
21. Barjesteh van Waalwijk van Doorn-Khosrovani S., Erpelinck C., van Putten W.L., Valk P.J., van der Poel-van de Luytgaarde S., Hack R., et al. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 2003, 101:837-845.
22. Schumacher J.A., Elenitoba-Johnson K.S., Lim M.S. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol 2008, 61:109-114.
23. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe against Cancer program. Leukemia 2003, 17:2318-2357.
24. Wang L., Lin D., Zhang X., Chen S., Wang M., Wang J. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients. Leuk Res 2005, 29:1393-1398.
25. Gorello P., Cazzaniga G., Alberti F., Dell'Oro M.G., Gottardi E., Specchia G., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20:1103-1108.
26. Niebuhr B., Iwanski G.B., Schwieger M., Roscher S., Stocking C., Cammenga J. Investigation of C/EBP alpha in human (versus murine) myelopoiesis provides novel insight into the impact of CEBPA mutations in acute myelogenous leukemia (AML). Leukemia 2009, 23:978-983.
27. Li X., Liu J., Zhou R., Huang S., Huang S., Chen X.M. Gene silencing of MIR22 in acute lymphoblastic leukemia involves histone modifications independent of promoter DNA methylation. Br J Haematol 2010, 148:69-79.
28. Tamase A., Muraguchi T., Naka K., Tanaka S., Kinoshita M., Hoshii T., et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009, 106:17163-17168.
29. Okamoto N., Yasukawa M., Nguyen C., Kasim V., Maida Y., Possemato R., et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A 2011, 108:20388-20393.
30. Sana J., Zambo I., Skoda J., Neradil J., Chlapek P., Hermanova M., et al. CD133 expression and identification of CD133/nestin positive cells in rhabdomyosarcomas and rhabdomyosarcoma cell lines. Anal Cell Pathol 2011, 34:303-318.
31. Romanova L., Kellner S., Katoku-Kikyo N., Kikyo N. Novel role of nucleostemin in the maintenance of nucleolar architecture and integrity of small nucleolar ribonucleoleoproteins and the telomerase complex. J Biol Chem 2009, 284:26685-26694.
32. Hwang K., Park C.J., Jang S., Chi H.S., Kim D.Y., Lee J.H., et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol 2012, 91:1541-1546.
33. Vergez F., Green A.S., Tamburini J., Sarry J.E., Gaillard B., Cornillet-Lefebvre P., et al. High levels of CD34+CD38low/CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Group Ouest-Est des leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011, 96:1792-1798.
34. Kramarzova K., Boublikova L., Stary J., Trka J. Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia-impact on minimal residual disease detection. Leukemia 2012, [E-pub ahead of print 10 October, 2012]. 10.1038/leu.2012.291.
35. Gaidzik V., Döhner K. Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. Semin Oncol 2008, 35:346-355.
36. Rosenfeld C., Cheever M.A., Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003, 17:1301-1312.
37. Cristóbal I., Garcia-Orti L., Cirauqui C., Cortes-Lavaud X., García-Sánchez M.A., Calasanz M.J., et al. Over expression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012, 97:543-550.
38. Weisser M., Kern W., Schoch C., Tschulik C., Hiddemann W., Haferlach T., et al. Reverse transcriptase-polymerase chain reaction based quantification of the combined MDS-EVI1/EVI1 gene in acute myeloid leukemia. Leuk Lymphoma 2006, 47:2645-2647.